Ariceum Therapeutics
Manfred Ruediger has a diverse work experience in the biotech and pharmaceutical industry. Manfred is currently serving as the CEO of Ariceum Therapeutics GmbH and a CEO in a stealth mode biotech company. Manfred is also the Chairman of the Board at Thermosome. In addition, they hold the role of a Member of the Supervisory Board at HeartBeat.bio AG. Manfred has previously held positions as a Member of the Supervisory Board at 4SC AG, Venture Partner at ALS Investmentfund, CEO at CatalYm GmbH, Beiratsvorsitzender at Apceth GmbH & Co.KG, and served on the Scientific Advisory Board at Medigene AG. Manfred also holds prior experience as the CEO of Kiadis Pharma.
Manfred Ruediger earned their PhD in Biochemistry and Molecular Biology from the University of Tübingen. Manfred attended the university from 1985 to 1991.
This person is not in any offices
Ariceum Therapeutics
1 followers
Ariceum Therapeutics is a privately held radiopharmaceutical firm in the clinical stage that specializes in the detection and targeted treatment of aggressive malignancies, such as neuroendocrine and other hard-to-treat cancers.177Lu-satoreotide tetraxetan (Satoreotide), the company's primary targeted systemic radiopharmaceutical therapy, isan antagonist of the somatostatin type 2 receptor (SSTR2), which is overexpressed in many neuroendocrine tumors. For the simultaneous diagnosis and targeted radionuclide treatment of neuroendocrine malignancies, some aggressive tumors, and childhood cancer, which currently offers few treatment choices and a poor prognosis, we are developing satoreotide as a "theranostic" pair.